Actual Medicinal Product (AMP) Ethosuximide 250mg capsules (Pilsco Ltd)

Stability Information

(Some stability information inherited from generic)

Stability

Lack of data and/or stability concerns exist. MCA use may be acceptable but is likely to be off-label and require mitigation measures. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or up to 8 weeks if the MCA is airtight (sealed). Consider the risk of potency loss or dose variability and monitor for changes in efficacy or adverse effects after MCA initiation.

Notes

Store in airtight containers.

Provenance

This compatibility recommendation is derived from generic ethosuximide 250mg capsules.

Generic

Ethosuximide

Formulation

Ethosuximide 250mg capsules

Alternative Suppliers (18)

Emeside 250mg capsules (Fontus Health Ltd)

Ethosuximide 250mg capsules (A A H Pharmaceuticals Ltd)

Ethosuximide 250mg capsules (Alliance Healthcare (Distribution) Ltd)

Ethosuximide 250mg capsules (Essential Generics Ltd)

Ethosuximide 250mg capsules (Accord Healthcare Ltd)

Ethosuximide 250mg capsules (Neuraxpharm UK Ltd)

Ethosuximide 250mg capsules (Strides Pharma UK Ltd)

Ethosuximide 250mg capsules (CST Pharma Ltd)

Ethosuximide 250mg capsules (Medihealth (Northern) Ltd)

Ethosuximide 250mg capsules (Aristo Pharma Ltd)

Epesri 250mg capsules (Strides Pharma UK Ltd)

Ethosuximide 250mg capsules (DE Pharmaceuticals)

Ethosuximide 250mg capsules (Necessity Supplies Ltd)

Zarontin 250mg capsules (Pfizer Ltd)

Zarontin 250mg capsules (Dowelhurst Ltd)

Ethosuximide 250mg capsules (Accord-UK Ltd)

Ethosuximide 250mg capsules (Pilsco Ltd)

Ethosuximide 250mg capsules (Noumed Life Sciences Ltd)

Related Formulations (1)

Ethosuximide 250mg capsules